Endovasc to Issue Stock Dividend in Nutraceutical Development Corporation; Basic Research to invest $2.5 Million in First Product.

Business Editors/Health/Medical Writers

MONTGOMERY, Texas--(BUSINESS WIRE)--Aug. 26, 2003

Endovasc Incorporated (OTCBB: EVSC) announced today that the Company's wholly-owned subsidiary, Nutraceutical Development Corporation, will be issuing a stock dividend to Endovasc stockholders of record on August 29, 2003.

Endovasc's Board of Directors will issue a dividend of one share of the Series Nutraceutical Development Corporation Common Stock for each four shares of Endovasc Inc. common stock.

In announcing the dividend, Dr. David P. Summers, CEO of Endovasc, said, "We have determined that our nutraceutical business could be a very lucrative segment for our angiogenic and stem cell recruitment technologies. Having recently signed a licensing agreement with Basic Research to invest a minimum of $2.5 million in developing, commercializing and marketing our Muscle Mass Technology, we felt now was an opportune time to reward our loyal shareholders for their ongoing support. Since the nutraceutical business is substantially different from our pharmaceutical business and will develop on its own schedule, we feel that the stockholders should receive the benefits of this segment through a separate class of stock whose performance and other attributes will reflect the business. We are currently developing and testing other new products with the intention of forming similar licensing and commercialization agreements."

All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the company and factors that are subject to uncertainties, risk and other influences, which are outside the company's control, and may yield results differing materially from those anticipated. The securities represented by this certificate have not been registered under the Securities Act of 1933 or the securities laws of any state and neither the securities represented by this certificate nor any beneficial interest therein may be sold, pledged, hypothecated or otherwise transferred except pursuant to an effective registration statement or as set forth in the certificate of designations, limitation, preferences and relative rights relating to the series NDC stock.